顺铂、阿霉素和依托泊苷联合方案与卡铂和紫杉醇联合方案治疗晚期和复发性子宫内膜癌的疗效比较。
Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.
作者信息
Olawaiye A B, Godoy H E, Shahzad M M K, Rauh-Hain J A, Lele S B, Odunsi K
机构信息
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh/Magee-Womens Hospital of UPMC, Pittsburgh, USA.
出版信息
Eur J Gynaecol Oncol. 2012;33(5):477-9.
OBJECTIVE
The objective of this study was to compare the efficacy of two multi-agent chemotherapeutic regiments that were previously used at the Institution for treatment of advanced and recurrent endometrial cancer.
METHODS
A retrospective review of patients with Stage III, IV, and recurrent endometrial cancer who received adjuvant chemotherapy at Roswell Park Cancer Institute over a period of 21 years. Two patient groups were defined based on treatment received: cisplatin, adriamycin, and VP-16 with or without megace (PAV-M), or carboplatin and paclitaxel (CT).
RESULTS
Forty-two patients with advanced or recurrent endometrial cancer were included in this review based on regimen received. Median duration of follow up was 55 months. Treatment with PAV-M resulted in more dose modifications compared to CT group (42% vs 11%, respectively). There were no significant differences in disease-free survival or overall survival.
CONCLUSIONS
PAV/PAV-M is active in patients with advanced or recurrent endometrial cancer. However, toxicity associated with this triplet regimen may limit clinical use.
目的
本研究的目的是比较该机构之前用于治疗晚期和复发性子宫内膜癌的两种多药化疗方案的疗效。
方法
对罗斯韦尔帕克癌症研究所21年间接受辅助化疗的III期、IV期和复发性子宫内膜癌患者进行回顾性研究。根据接受的治疗定义了两个患者组：顺铂、阿霉素和VP - 16联合或不联合甲地孕酮（PAV - M），或卡铂和紫杉醇（CT）。
结果
根据接受的方案，本综述纳入了42例晚期或复发性子宫内膜癌患者。中位随访时间为55个月。与CT组相比，PAV - M治疗导致更多的剂量调整（分别为42%和11%）。无病生存期或总生存期无显著差异。
结论
PAV/PAV - M对晚期或复发性子宫内膜癌患者有效。然而，与该三联方案相关的毒性可能会限制其临床应用。
Zotero 插件